



Received on 23 March 2020; received in revised form, 30 April 2020; accepted, 15 May 2020; published 01 March 2021

THE STUDY ON OPTIMIZATION OF SOLID ORAL FLOATING TABLETS - A REVIEW

Rajesh Pawar ^{*1} and Swati Jagdale ²

MAEER's Maharashtra Institute of Pharmacy ¹, MIT Campus, Kothrud, Pune - 411038, Maharashtra, India.

School of Pharmacy ², Dr. Vishwanath Karad MIT World Peace University, MIT Campus, Kothrud, Pune - 411038, Maharashtra, India.

Keywords:

Floating drug delivery systems, Single-Unit Dosage Forms, Multi-dose, Kinetics

Correspondence to Author:

Rajesh Pawar

Ph.D. Research Scholar,
MAEER's Maharashtra Institute of
Pharmacy, MIT Campus, Kothrud,
Pune - 411038, Maharashtra, India.


E-mail: rajesh.pawarmit@yahoo.com

ABSTRACT: The motivation behind composing this review on floating drug delivery systems (FDDS) was to incorporate the ongoing research article with a unique spotlight on the key system of floatation to accomplish gastric maintenance. The ongoing advancements of FDDS, including the physiological and formulation factors influencing gastric maintenance, ways to deal with configuration single-unit, and numerous unit of floating drug delivery systems, and their grouping and formulations perspectives are canvassed in detail. This review has a special focus on the principal mechanism of floatation to achieve gastric retention. Conventional oral dosage forms have short residence times & unpredictable gastric emptying time. The idea of gastric retention comes from the need to localize drugs at a specific region of the gastrointestinal tract (GIT), such as the stomach in the body. Many drugs get absorbed only in the upper intestinal tract, designing such molecules as once-daily formulations are exclusive for these molecules. Thus, gastro retention could help to provide greater availability of new products and consequently improved therapeutic activity and substantial benefits to patients. This article aims at reviewing the floating drug delivery system, including types, approaches for designing the floating dosage form, advantages & disadvantages of FDDS. This drug delivery system is valuable to a few issues experienced during the advancement of a pharmaceutical dosage form.

INTRODUCTION: Floating Drug Delivery Systems (FDDS) have a mass thickness lower than gastric liquids and, in this manner, stay light in the stomach for a delayed timeframe without influencing the gastric discharging rate.

While the dosage form float on gastric juice, sedate is discharged gradually at an ideal rate from the dosage form. After the arrival of the drug, the remaining dosage form is exhausted from the stomach. This outcome is an increment in GRT and superior control of changes in plasma tranquilizes focuses. Floating dosage forms can be characterized into two kinds, non-effervescent dosage form, and effervescent dosage form ¹⁻⁵.

Types of Floating Drug Delivery Systems (FDDS): The accompanying methodologies have been utilized for the plan of floating measurement types of single-and various unit systems.

QUICK RESPONSE CODE 	DOI: 10.13040/IJPSR.0975-8232.12(3).1399-11
	The article can be accessed online on www.ijpsr.com
DOI link: http://dx.doi.org/10.13040/IJPSR.0975-8232.12(3).1399-11	




FIG. 1: CLASSIFICATION OF FDDS

Single-Unit Dosage Forms: In the Low-thickness approach, the globular shells having lower thickness than that of gastric liquid can be utilized as a bearer for medicating for its controlled discharge. A light dose structure can likewise be acquired by utilizing a liquid-filled dosage form that floats in the stomach. In covered shells popcorn, price, what's more, polystyrol has been abused as drug bearers. Sugar polymeric materials, for example, methacrylic polymer and cellulose acetic acid derivation phthalate have been utilized to undercoat these shells. These are additionally covered with a drug-polymer blend. The polymer of a decision can be either ethylcellulose or hydroxypropyl cellulose, relying upon the kind of discharge wanted. At long last, the item coasts on the gastric liquid while discharging the drug bit by bit over a drawn-out span⁶⁻⁸.

Liquid-filled floating chamber kind of dose structures incorporates the joining of a gas-filled floatation chamber into a microporous part that houses a drug supply. Gaps or openings are available along with the top and base dividers

through which the gastrointestinal tract liquid enters to break up the drug. The other two dividers in contact with the liquid are fixed with the goal that the undissolved drug remains in that. The liquid present could be air, under fractional vacuum, or some other appropriate gas, fluid, or strong having a proper explicit gravity and inactive conduct. The gadget is of swallowable size, stays above water inside the stomach for a drawn-out time, and after the total discharge, the shell crumbles give to the digestive system and is dispensed with.

Hydrodynamically adjusted dosage forms (HBS) are intended to drag out the stay of the measurement structure in the gastrointestinal tract and help in upgrading the assimilation. Such dosage forms are most appropriate for drugs having superior solvency in acidic conditions and for the drugs having an explicit site of retention in the upper piece of the small digestive tract. It should remain in the stomach, keep up its auxiliary honesty, furthermore, discharge sedate continually from the dose structure.

The achievement of the HBS case as an extended-release dosage form is best exemplified with chlordiazepoxide hydrochloride^{9, 10}. HBS of chlordiazepoxide hydrochloride had an equivalent blood level time profile starting at three 10-mg marketed products. Numerous polymers and polymer blends with wet granulation as an assembling system have been investigated to yield floatable tablets.

Different kinds of tablets (bilayered and matrix) have been appeared to have floatable qualities. A portion of the polymers utilized is hydroxypropyl cellulose, hydroxypropyl methylcellulose, crospovidone, sodium carboxymethyl cellulose, and ethyl cellulose. Self-adjusting floatable topsy-turvy arrangement tranquilize conveyance system employs an unbalanced 3-layer network innovation to control sedate discharge.

The 3-layer standard has been improved by an asymmetric configuration drug delivery system in request to regulate the discharge degree and accomplish zero-order discharge energy by at first keeping up a consistent territory at the diffusing front with ensuring disintegration/disintegration toward the finish of the discharge procedure. The system was planned in such a way that it floats to draw out gastric retention time *in-vivo*, bringing about longer all-out travel time inside the gastrointestinal tract condition with the most extreme absorptive limit and thus more noteworthy bioavailability. This specific trademark would be pertinent to drugs with pH-subordinate solvency, a limited window of assimilation, and are consumed by dynamic vehicles from either the proximal or distal segment of the small digestive tract. Single-unit formulations are associated with sticking together or being obstructed in the gastrointestinal tract, which may have a potential danger of producing irritation.

Multiple-Unit Dosage Forms: The reason for structuring different unit measurement structures is to build up a dependable plan that has all the benefits of a solitary unit structure and is without any of the abovementioned referenced disservices of single-unit plans. In a quest for this undertaking, numerous various unit floatable measurement structures have been planned. Microspheres have a high stacking limit, and numerous polymers have

been utilized, such as egg whites, gelatin, starch, polymethacrylate, polyacrylamide, and poly alkyl cyanoacrylate. Round polymeric microspheres, additionally alluded to as "micro balloons," have been arranged. Microspheres have a trademark inside an empty structure and show brilliant *in-vitro* flowability. In Carbon dioxide-producing different unit oral formulations, a few gadgets with highlights that broaden, unfurl, or are swelled via carbon dioxide produced in the gadgets after the organization has been depicted in the ongoing patent writing. These measurement structures are avoided from the section of the pyloric sphincter if a distance across of ~12 to 18 mm in their extended state is surpassed^{11, 12}. Amena. *et al.*, (2019)¹³ prepared and evaluated floating tablets of sitagliptin which is based on the effervescent approach using sodium bicarbonate in which carbon dioxide acted as a releasing agent. Formulator coalesces Sitagliptin, Gum and Guar gum, Microcrystalline cellulose (MCC), sodium bicarbonate, citric acid, Magnesium Stearate polymers in 100 mg, 140 mg, 7 mg, 35 mg, 12 mg, 6 mg, respectively as a best-optimized(S9) formulation its kinetics values mentioned in **Table 1**. The formulator used a 40% concentration of Guar gum and 35% of sodium bicarbonate as a floating agent to optimize the best formulation of 12 h release time and floating lag time respectively.

TABLE 1: KINETICS VALUE OF S9 FORMULATION

	Zero %CD R vs. T	First Log % remain, vs. T	Higuchi %CR R vs. T	Peppas Log C vs. Log T
Slope	7.9	-0.1146	30.35	1.3
Intercept	11.14	2.11	-9.78	0.76
Correlation R ²	0.9272 0.944	-0.96 0.9276	0.98 0.9716	0.84 0.716

Sharma Aditya *et al.*, (2019)¹⁴ developed a novel gastro retentive drug delivery system of Tropisetron for active release by using Tropisetron, Carbopol, sodium carbonate, magnesium stearate, citric acid, talc, and lactose in 50mg, 50mg, 20mg, 30 mg, 5 mg, 15 mg, 25 mg respectively as the best formulation blend (F7), sodium bicarbonate and anhydrous citric acid used to directly compress floating tablets. The optimized formulation (F7) exhibited a 63.87% drug release in 12 h emerged as the best formulation based on drug release characteristics and *in-vitro* drug release study shown in **Table 2**.

TABLE 2: IN-VITRO DRUG RELEASE STUDY¹⁴

Time(Hr)	F1 %CDR	F2 %CDR	F3%CDR	F4 %CDR	F5 %CDR	F6 %CDR	F7 %CDR
1	18.90	8.31	7.01	6.5	7.89	6.5	4.23
2	40.33	15.02	11.22	9.8	11.6	9.91	6.28
3	51.33	27.02	17.95	14.3	16.13	14.02	10.98
4	60.28	31.02	21.01	23.2	20.71	17.09	15.97
5	67.28	37.02	29.24	27.6	28.78	22.5	21.95
6	78.23	44.34	36.01	35.3	33.48	30.76	28.32
7	85.61	49.39	43.24	42.68	39.48	37.83	34.63
8	98.74	52.00	51.52	46.68	49.52	41.79	39.12
9		59.03	58.28	51.56	57.52	49.28	44.66
10		68.12	63.30	57.90	65.84	53.89	50.36
11		72.24	71.63	64.26	70.27	62.53	56.56
12		77.87	76.75	65.82	76.56	67.66	63.87

Tulshi Chakraborty *et al.*, (2019)¹⁵ prepared and evaluated controlled release floating tablets of Cefixime, polyvinyl alcohol, sodium bicarbonate, citric acid, ethylcellulose, beeswax, carbopol-934, magnesium stearate, talc, in 200 mg, 60 mg, 45 mg,

25 mg 70 mg, 80 mg, 52 mg, 15 mg, 13 mg as an F4 batch controlled release floating tablets of the best choice for which drug released shown in **Table 3**. Sodium bicarbonate and citric acid are used as floating agents.

TABLE 3: CUMULATIVE % DRUG RELEASE OF TABLETS¹⁵

Time	F1	F2	F3	F4	F5	F6	F7	F8	F9
1	8.11	9.21	9.59	11.49	8.86	70.71	9.31	9.09	8.78
2	12.23	13.67	16.51	22.63	16.56	16.65	16.78	15.35	14.42
3	20.86	20.63	24.46	31.52	23.63	20.27	23.26	22.44	21.58
4	27.52	30.31	35.49	40.45	34.56	34.53	34.45	32.64	31.91
5	39.01	40.44	47.53	49.56	46.6	48.68	46.7	44.65	42.34
6	46.78	46.6	53.33	58.59	52.36	55.64	53.3	50.45	48.5
7	53.04	55.42	59.59	66.6	58.55	65.67	57.71	57.2	56.33
8	56.73	57.5	64.64	71.4	64.4	71.38	64.9	61.3	59.3
9	60.49	61.37	69.49	73.61	82.57	73.19	81.67	72.35	70.27
10	61.6	67.49	73.61	82.57	73.19	81.67	72.35	70.27	68.28
11	66.66	71.69	78.56	90.51	77.5	87.67	72.35	70.27	68.28
12	71.26	73.61	84.46	98.48	83.68	93.48	81.56	77.35	75.09

Airmen *et al.*, (2019)¹⁶ formulated an effervescent floating drug delivery system of metformin in which Metformin (500 mg), Grewia mollies (GM) gum (2, 4, 6 8% w/w), Eudragit RL100 (1%), Sodium bicarbonate (30%), Tartaric acid (5%), Talc (1%) Lactose (QS) is used. Sodium bicarbonate (30%) and tartaric acid (5%) as gas generating agents. Grewia Mollis gum has been exploited in the formulation of gastro-floating matrix tablets of metformin which may find useful application for drugs that have a narrow absorption window in the upper part of the gastrointestinal tract (GIT). It was noticed that with an increase in the binder concentration of the GM gum, there was a significant increase in the hardness of the tablet. It was observed that an increase in the concentration of GM gum caused a significant increase in the FLT. The indication is that the addition of Eudragit RL100 helped to increase the

integrity of the tablet formulation, therefore, showing a buoyancy duration of > 12 h. This study discovered that Grewia Mollis Gum can be used in the formulation of the gastro floating drug delivery system of metformin, and this can be beneficial in the formulation of the controlled release dosage form of metformin.

Chinna eswaraiyah *et al.*, (2019)¹⁷ clarifies the effervescent floating matrix tablet of metronidazole and assesses the impact of fluctuating groupings of hydrophilic polymers on sedate discharge. Drug excipients association was concentrated by Fourier change infrared spectrophotometer. The effervescent floating matrix tablets were set up by direct pressure procedure utilizing hydroxypropyl methylcellulose (HPMCK4) and thickener alone and in the mix as discharge retardants. Micro-crystalline cellulose was utilized as diluent.

Sodium bicarbonate was utilized as an effervescent agent. The readied dosage form tablets were assessed for their physicochemical parameters such as weight variety, hardness, friability, content consistency, lightness time, and *in-vitro* disintegration. Micromeritic properties and post-pressure parameters were assessed, and all the parameters were found inside complying. The drug discharge information we're exposed to various models to assess release kinetics and a mechanism of drug discharge. The tablets formulate with

xanthan gum, and a blend of xanthan gum and HPMCK4M have impeded the drug discharge up to 12 h. The discharge component of metronidazole was assessed based on discharge type as per in Peppas model shown in **Table 5**. The n estimation of the formulations went from 0.46 to 0.89, which demonstrated Case II transport and zero-order discharge. Floating Matrix tablet is a straight-forward, proficient, and economical technique to continue the arrival of metronidazole to annihilate *Helicobacter pylori* in peptic ulcers.

TABLE 4: CORRELATION COEFFICIENT AND RELEASE KINETICS GRFMT OF METFORMIN (N=3) PREPARED WITH VARYING CONCENTRATION OF GMG ¹⁷

Model Formulations	Zero		First		Higuchi		Korsmeyer and Peppas	
	r ²	K0	r ²	K1	r ²	KH	r ²	n
GM1	0.80	25.43	0.94	-0.48	0.95	47.64	0.95	0.51
GM2	0.84	23.05	0.94	-0.25	0.98	38.95	0.98	0.48
GM3	0.83	24.25	0.96	-0.13	0.98	31.41	0.97	0.46
IG4	0.86	21.92	0.95	-0.11	0.99	28.71	0.96	0.46
IG5	0.90	19.46	0.97	-0.09	0.99	28.14	0.98	0.47

TABLE 5: CORRELATION COEFFICIENTS (R) VALUES OF DRUG RELEASE KINETICS AND MECHANISM OF FLOATING MATRIX TABLETS OF METRONIDAZOLE ¹⁷

Formulations	Zero-order	First Order	Higuchi	Peppas		Hixson-Crowell
				R ²	n	
F1	0.826	0.971	0.975	0.957	0.46	0.990
F2	0.881	0.960	0.995	0.991	0.47	0.996
F3	0.953	0.949	0.973	0.979	0.75	0.996
F4	0.976	0.890	0.962	0.982	0.89	0.979
F5	0.979	0.781	0.936	0.988	0.80	0.890
F6	0.989	0.59	0.944	0.994	0.85	0.978
F7	0.975	0.761	0.971	0.991	0.80	0.944
F8	0.955	0.896	0.970	0.990	0.78	0.983
F9	0.992	0.938	0.955	0.996	0.86	0.980

Shu Wang *et al.*, (2019) ¹⁸ examined the formulations and assessment of gastric-floating controlled discharge tablets of Ginkgolides. The researcher used a pressure technique joined with a hydrophilic polymer, floating associate agents, and effervescent substance. Details were assessed for *in-vitro* drug discharge, *in-vitro* floating capacity and *in-vivo* gastro-retentive conduct by gamma scintigraphy method extended drug discharge characteristic for 12 h. The discharge practices of the tablets were fitted to the zero-order model in the coupled activity of drug dissemination and

matrix disintegration instrument shown in **Table 6**. *In-vivo* practices of the tablets were seen at various time interims from the radiographic photos of the healthy volunteers and the maintenance time in the stomach was around 8 h. Results mentioned that gastric-floating tablets of the Ginkgolides had the potential for decent gastric home time and the controlled drug discharge. The optimized formulations showed good instant and total duration floating properties and extended drug release characteristic for 12 h.

TABLE 6: KINETIC RELEASE EQUATIONS OF DIFFERENT MODELS FOR OPTIMIZED FORMULATION ¹⁸

Model	GA	r ²	GB
	Equation		Equation
Zero order	Qt = 6.4343t+3.7578	0.9951	Qt = 6.4636t+3.8029
First order	ln (100-Qt) = 0.1090t+4.6175	0.9768	ln (100-Qt) = 0.1111t+4.6214
Higuchi	Qt=23.3282t ^{1/2} -9.2434	0.9414	Qt=23.5241t ^{1/2} -9.4399
Korsmeyer- Pappas	Qt=9.6905t ^{0.845}	0.9979	Qt=10.1084t ^{0.828}

Ranjit Prasad Swain *et al.*, (2019) ¹⁹ explained blend treatment of ezetimibe and atenolol which is profoundly alluring for better administration of dyslipidemia and hypertension. Ezetimibe has poor solvency as a result of lower bioavailability. Atenolol has poor retention in the lower gastrointestinal tract, short half-life. In this way, the present investigation was to create a gastro-bilayer floating matrix tablet in which ezetimibe was consolidated as a prompt layer and atenolol as a supported discharge layer. Solvency of the ezetimibe was improved by a strong scattering method and was described by FTIR, DSC and XRD study. Gastrobilayer floating tablets were set up by

direct pressure technique. Hydroxypropyl methyl-cellulose K100 (37.5% w/w) as discharge retardant and croscarmellose sodium (15% w/w) as super disintegrants in the quick layer as upgraded. The all-out floating time of the optimized tablet was 12 h with 9 min of floating lag time. Atenolol discharge was supported through a dissemination system more than 12 h, and more than 95% ezetimibe was discharged within 30 min. It very well may be reasoned that biphasic sedate discharge design was effectively accomplished through the formulations of gastro-floating bilayer tablets right now, reinforced mix treatment for hypertension and dyslipidemia.

TABLE 7: RELEASE KINETICS OF OPTIMIZED FORMULATION ¹⁹

Formulation	Zero-order		First-order		Higuchi	Korsmeyer and peppas		Hixon crowell		
	r ²	K ₀	r ²	K ₁		K _H	r ²	N	r ²	K
GBF2	0.870	6.340	0.859	0.077	0.974	25.61	0.969	0.355	0.761	0.011

Ali Raza *et al.*, (2017) ²⁰ Completed an examination meant to formulate gastro retentive floating tablets of minocycline hydrochloride with wanted floating properties, wanted drug-discharge rate, its nearby activity in the stomach for treatment of H. Pylori infection and avoidance of a reaction, pseudomembranous colitis. A simplex-mixture blend configuration was utilized to get the trial design. Methocel K100LV, Methocel K15M, and Carbopol 934 were chosen as independent factors. Ten formulations (F1 to F10) were created by direct compression and were assessed for physical parameters, growing index, floating lag time, floating time, and *in-vitro* drug-discharge rate. Moreover, FTIR spectroscopic investigations were performed to decide the drug-polymer connection. Floating lag time, floating time, total drug discharge at 3 h, 6 h, and 12 h were chosen as needy factors. Kinetic models of drug release for all formulations shown in **Table 8** Results

indicated that floating lag time and floating time were diminished by the presence of Carbopol 934 in detail while at the same time expanding by Methocel K100LV and Methocel K15M. The presence of Carbopol 934 additionally caused an expansion in the drug-discharge rate, while Methocel K100LV and Methocel K15M contributed to the diminishing discharge rate. Except for F1, the various plans showed floating time > 12 h. Based on enhancement criteria, the composition of optimized formulations F10 (Methocel K100LV=7.98 mg and Carbopol 934=82.02 mg) was dictated by the measurable investigation. FTIR spectroscopic investigations demonstrated that no connection was found among polymers and drugs. Compactly, inferred that Carbopol 934 and Methocel 100LV can be utilized to create gastro retentive floating tablets of minocycline hydrochloride with great lightness properties and supported discharge activity.

TABLE 8: KINETIC MODELS OF DRUG RELEASE FOR ALL FORMULATIONS ²⁰

Formulation	Zero Order		First-order		Higuchi		Korsmeyer		n
	R2	ko	R2	k1	R2	kh	R2	kP	
F1	0.9827	17.26	0.8704	0.29	0.7882	34.26	0.9834	18.11	0.968
F2	0.8972	5.81	0.9925	0.08	0.936	16.62	0.993	11.31	0.693
F3	0.9795	4.8	0.9968	0.06	0.8793	13.53	0.9986	6.87	0.836
F4	0.9827	5.02	0.9916	0.07	0.8742	14.12	0.9982	6.98	0.849
F5	0.8621	5.72	0.9813	0.08	0.9559	16.46	0.997	12.08	0.655
F6	0.9615	8.74	0.9507	0.16	0.8711	24.64	0.9848	12.87	0.822
F7	0.9894	7.45	0.9614	0.12	0.8593	20.88	0.9984	9.64 0	.882
F8	0.6126	5.54	0.8629	0.08	0.9894	16.19	0.9916	15.29	0.529
F9	0.9377	7.35	0.9895	0.12	0.9227	20.92	0.9992	12.98	0.738
F10	0.8751	6.75	0.995	0.11	0.9486	19.37	0.9951	13.85	0.668

Faria Senjoti *et al.*, (2016)²¹ taken an effort on oral sustained-release floating tablet detailing of metformin HCl was structured and created. Effervescence and swelling properties were ascribed on the created tablets by sodium bicarbonate and HPMC-PEO polymer mix, individually. Tablet formation was optimized by the response surface methodology (RSM). Seventeen preliminary formulations were broke down as indicated by the Box-Behnken design where polymer substances of HPMC and PEO at 1: 4 proportions, the amount of sodium bicarbonate, and SSG were received as independent variables. Floating lag time in a sec, cumulative percent drug released at 1 h and 12 h were picked as response variables. Tablets from the optimized formulation were additionally put away accelerated stability conditions for 3 months to evaluate their stability profile. RSM could effectively enhance tablet composition with fantastic forecast capacity. *In-vitro* drug discharge until 12 h, floating lag time, and length of floating were subject to the measure of three chosen independent variables. Optimized tablets stayed floating for more than 24 h with a floating lag time of under 4 min. Given the best fitting strategy, the optimized formulation was found to follow the Korsmeyer-Peppas discharge kinetics. An accelerated stability study uncovered that improved formulations were steady for a quarter of a year with no significant changes in assay, disintegration profile, floating lag time, and other physical properties.

Swati Rawat *et al.*, (2018)²² Floating Drug Delivery Systems (FDDS) have a mass thickness lower than gastric liquids and in this way stay light in the stomach for a drawn-out timeframe, without influencing the exhausting gastric rate. While the dosage form is floating on the gastric substance, the

drug is discharged gradually at an ideal rate from the dosage form. These floating tablets, for the most part, are arranged for a decrease of lag time and discharge the drug as long as 12 h and may likewise build the bioavailability of the drugs by using the drug to full degree, staying away from the pointless recurrence of dosing.

TABLE 9: SUMMARY OF MATHEMATICAL MODELING OF RELEASE PROFILE OF AN OPTIMIZED FORMULATION²¹

Model	Parameter
Zero-order	k0 = 8.665, R2 = 0.725, AIC = 50.477
First order	k1 = 0.177, R2 = 0.965, AIC = 36.147
Hixon crowell	kHC = 0.048, R2 = 0.940, AIC = 39.818
Higuchi	kH = 25.700, R2 = 0.994, AIC = 24.127
Kormeyer peppas	kKP = 23.314, n = 0.548, R2 = 0.999, AIC = 15.536
Weibull	$\alpha = 147.810, \beta = 2.037, \text{Ti} = -5.424, R2 = 0.997, \text{AIC} = 22.020$

The examination included formulations of floating tablets utilizing polymers like Hydroxypropyl methylcellulose K15M, PVP K30, Sodium bicarbonate, Xanthan-Gum, Guar-gum, and microcrystalline cellulose as lattice shaping operators. The tablets were straightforwardly compacted utilizing a Lab Press multi-station revolving punching machine. FTIR and DSC-TGA examine adjusted that there was no incongruence between the polymers and the drug. Tablet formulation parameters were inside as compliance. Tablet indicated zero lag time, duration of floating for >12 h. *In-vivo* X-beam examines delineated that tablets kept on floating in the GIT for 12 h. The *in-vitro* sedate discharge example of Acyclovir floating tablets was fitted to various dynamic models, which demonstrated the most elevated relapse for zero-order energy with Koresmeyer-Pappas, and the greater part of the formulations followed Non-fickian diffusion.

TABLE 10: IN-VITRO DRUG RELEASE OF FORMULATION²²

S. no.	F1	F2	F3	F4	F5	F6	F7	F8	F9
1	9.84	9.65	8.1	13.58	9.93	8.4	12.76	10.5	9.01
2	16.31	14.85	14.13	16.24	16.31	14.85	18.14	17.5	15.13
3	22.43	23.43	21.15	24.07	23.61	22.15	25.17	24.07	22.98
4	28.36	27.9	26.63	29.82	28.82	27.26	31.01	29.27	28.27
5	34.2	32.01	31.01	35.57	33.74	31.83	44.24	35.57	33.65
6	44.24	43.51	34.2	45.33	42.96	39.4	51.08	43.51	41.59
7	50.26	48.53	44.33	52.36	49.53	44.78	53.82	52.92	49.35
8	57.56	56.19	52.63	59.66	58.93	53.45	60.66	57.92	9.84
9	68.78	67.6	62.3	72.16	68.78	63.03	72.89	69.88	66.89
10	75.81	74.99	69.49	78.55	77.18	69.88	79.92	78.18	72.89
11	88.31	87.03	80.01	80.04	98.95	81.74	89.5	88.77	86.3
12	96.35	92.42	87.67	97.35	93.6	88.68	98.68	94.15	89.2

Q li *et al.*, (2019)²³ projected three-dimensional (3D) expulsions-based printing is a paste-based fast-prototyping process, which is fit for building complex 3D structures. The point of this examination was to investigate the feasibility of 3D expulsion-based printing as a pharmaceutical assembling procedure for the manufacture of gastro-floating tablets. Novel low-thickness cross-section inward structure gastro-floating tablets of dipyrindamole were created to drag out the gastric home time to improve the drug-release rate and subsequently improve bioavailability and therapeutic viability. Excipients regularly utilized in the pharmaceutical examination could be productively applied in the room-temperature 3D expulsion-based printing process. The tablets were planned with three sorts of infill percentages and arranged by hydroxypropyl methylcellulose (HPMC K4M) and hydroxypropyl methylcellulose

(HPMC E15) as hydrophilic networks and microcrystalline cellulose (MCC PH101) as expulsion forming specialist. *In-vitro* assessment of the 3D printed gastro-floating tablets was performed by deciding mechanical properties, content consistency, and weight variety. Moreover, re-floating capacity, floating-term time, and drug release conduct were likewise assessed. Disintegration profiles uncovered the connection between infill rate and drug release conduct. The aftereffects of this examination uncovered the capability of 3D expulsion-based printing to create gastro-floating tablets with more than 8 or floating procedures with conventional pharmaceutical excipients and interior grid structure plans. Results of fitting experimental release from dipyrindamole floating tablets *in-vitro* release profiles to shown in **Table 11**.

TABLE 11: RESULTS OF FITTING EXPERIMENTAL RELEASE, FROM DIPYRIDAMOLE FLOATING TABLETS *IN-VITRO* RELEASE PROFILES TO (A) ZERO-ORDER, (B) FIRST-ORDER, (C) HIGUCHI AND (D) KORSMEYER PEPPAS KINETIC EQUATIONS²³

Filling rate	Zero-order(r2)	The first order(r2)	Higuchi(r2)	Korsmeyer-Peppas(r2)	n value
30%	0.7274	0.7299	0.9979	0.9981	0.489
50%	0.6646	0.6676	0.9914	0.9943	0.458
70%	0.8722	0.8738	0.9829	0.9951	0.603




FIG. 2: DRUG RELEASE PROFILES OF THE FORMULATIONS USED IN THE EXPERIMENTS (N=6): (A) COMPARISON OF COMMERCIAL FAST-RELEASE TABLETS AND DOM-FSR TABLETS, (B) THE INFLUENCE OF SHELL NUMBERS, (C) THE INFLUENCE OF INFILL PERCENTAGES, AND (D) COMPARISON OF THE TABLETS WITH OPTIMIZED PARAMETERS, TABLETS USED FOR PHARMACOKINETIC STUDY AND TABLETS USED FOR X-RAY IMAGING²³

X. Chai *et al.* (2017)²⁴ examine the attainability of combined confirmation displaying 3D prints to get ready intragastric floating continued release tablets. Domperidone, an insoluble weak base, was picked as a model drug to explore the capability of FSR in expanding its oral bioavailability and decreasing its regimen frequency. DOM has effectively stacked into hydroxypropyl cellulose fibers utilizing hot-soften expulsion. The fibers were then printed into empty organized tablets by changing the shell numbers and the infill rates. Physical portrayal results showed that most of the DOM step by step transformed into the nebulous structure during the manufacturing procedure.

The streamlined formulation displayed the continued release trademark and had the option to drift for around 10 h *in-vitro*. Radiographic pictures demonstrated that the BaSO₄- labeled tablets were held in the stomach of rabbits for more than 8 h. Moreover, pharmacokinetic studies demonstrated the overall bioavailability of the FSR tablets contrasted and reference marketed tablets was $222.49 \pm 62.85\%$. All the outcomes indicated that FDM-based 3D printing might be a promising method to manufacture hollow tablets with the end goal of intragastric floating drug delivery. Drug release profiles of the formulations used in the experiments are shown in **Fig. 1**.

Péter Diós *et al.*, (2015)²⁵ concentrated on planning a local, floating, mucoadhesive drug delivery framework containing metronidazole for

Helicobacter pylori destruction. The face-focused focal composite structure was utilized for the assessment and streamlining of *in-vitro* floating and disintegration examines. Sodium alginate, low-subbed hydroxypropyl cellulose, and sodium bicarbonate focuses were the free factors in the advancement of effervescent floating tablets.

All tablets indicated worthy physicochemical properties. The factual investigation uncovered that tablets with 5.00A% sodium alginate, 38.63% L-HPC B1 and 8.45% sodium bicarbonate substance *in-vitro* demonstrated promising floating and disintegration properties for additional assessments. Optimized floating tablets communicated astounding floating power. They are *in-vitro* disintegration examines were contrasted, and two commercially accessible non-floating metronidazole products and afterward microbiologically recognized disintegration, *ex-vivo* separation power, rheological mucoadhesion studies, and similarity considers were completed.

Model dependent evaluation of dissolution data shown in **Table 12** significant likenesses (f1, f2) between *in-vitro* spectrophotometrically and microbiologically identified disintegrations was found. Studies uncovered noteworthy *ex-vivo* mucoadhesion of optimized tablets, which were impressively expanded by L-HPC. *In-vivo*, X-beam CT investigations of optimized tablets indicated 8-h gastro maintenances in rodents represent by an animation arranged by a unique CT procedure.

TABLE 12: MODEL DEPENDENT EVALUATION OF DISSOLUTION DATA²⁵

Formulations	Zero order model R2	First order model R2	Higuchi model R2	Weibull model R2
MF1	0.509	0.678	0.693	0.728
MF2	0.964	0.969	0.980	0.939
MF3	0.518	0.896	0.693	0.860
MF4	0.857	0.883	0.944	0.758
MF5	0.373	0.500	0.546	0.664
MF6	0.808	0.812	0.888	0.917
MF7	0.658	0.817	0.78	9 0.891
MF8	0.900	0.909	0.972	0.919
MF9	0.481	0.771	0.657	0.785
MF10	0.911	0.91	9 0.940	0.906
MF11	0.934	0.942	0.946	0.942
MF12	0.954	0.963	0.977	0.900
MF13	0.958	0.963	0.962	0.909
MF14	0.897	0.907	0.959	0.858
MF15	0.960	0.961	0.946	0.887
MFOPT	0.524	0.820	0.690	0.816
Klion	0.497	0.618	0.671	0.866
Supplin	0.833	0.897	0.899	0.953

Huanbutta *et al.*, (2019) ²⁶ developed three-dimensional printing advancements that are broadly utilized in clinical applications, mirroring the simplicity of customization and personalization. Henceforth, uses of 3D imprinting in pharmaceutical assembling may give assortment and unpredictability of pharmaceutical measurement frames that customary techniques don't. 3D printing can be utilized to deliver individualized drug and measurement structures for future restorative applications. Thus, we built up a pharmaceutical formulation as a floating controlled drug discharge tablet stacked with a metronidazole center utilizing 3D printing. The floating shell or tablet lodging was set up from polyvinyl alcohol. At first, states of tablet floating lodgings were

structured and imprinted in the chamber, circle, and cone shapes. Metronidazole tablet centers were then arranged by direct pressure and were gathered into the printed tablet lodging. The researcher analyzed the impacts of states of the floating tablet lodging, shaft sizes for tranquilizing discharge, and air volumes for floating. Tube-shaped floating tablet lodgings floated steadily at the outside of the water. These tablets likewise floated quickly and for more than 4 h, and drug discharge, where over 88% after 8 h. linear regression modeling and drug release kinetics were mentioned in **Table 13**. Floating tablets with pore sizes of 2.0 mm and air volumes of 132 mm³ gave zero-order tranquilizes discharge in active examinations, with an r² estimation of 0.9661.

TABLE 13: LINEAR REGRESSION MODELING AND DRUG RELEASE KINETICS OF METRONIDAZOLE-LOADED 3D PRINTED TABLETS ²⁶

Air volume (mm ³)	Drug release pore size diameter (mm)	Printing material	Zero-order r ²	First-order r ²	Higuchi r ²	Korsmeyer-Pappas r ²	n	Drug transport mechanism
132	1.5	PVA	0.9582	0.7978	0.0427	0.9655*	1.28	Super case II transport
2132	2.0	PVA	0.9661*	0.7784	0.0478	0.9505	1.27	Super case II transport
132	2.5	PVA	0.9671	0.7472	0.3080	0.9791*	1.09	Super case II transport
264	2.0	PVA	0.9601*	0.8042	0.2942	0.9493	1.04	Super case II transport
396	2.0	PVA	0.9638*	0.9263	0.3491	0.9017	0.86	Non – Fickian transport
132	2.0	ABS	0.9498*	0.8644	0.2960	0.9339	0.98	uper case II transport

Kadivar *et al.*, (2015) ²⁷ Studied Imatinib mesylate, which is an antineoplastic specialist, has high ingestion in the upper piece of the gastrointestinal tract. Traditional imatinib mesylate (Gleevec) tablets produce quick and generally high pinnacle blood levels and require frequent administration to keep the plasma drug level at a powerful range. This may cause symptoms, decreased adequacy, and poor therapeutic administration. Along these lines, floating continued release Imatinib tablets were created to permit the tablets to be released in the upper piece of the GIT and defeat the deficiency of traditional tablets. Technique: Floating continued release Imatinib mesylate tablets were readied utilizing the wet granulation strategy. Tablets were defined utilizing Hydroxypropyl Methylcellulose, with Sodium alginate and Carbomer 934P as release-impeding

polymers, sodium bicarbonate as the effervescent specialist, and lactose as a filler. Floating conduct, *in-vitro* drug release, and growing file examines were directed. Starting and absolute drug release length was contrasted, and a marketed tablet in 0.1 N HCl (pH 1.2) at 37 ± 0.5 °C for 24 h. Tablets were then assessed for different physical parameters, including weight variety, thickness, hardness, friability, and drug content. Subsequently, a half year of physical dependability examination and *in-vitro* gastro-retentive examinations were directed. Measurable information investigation uncovered that tablets containing a synthesis of 14.67% w/w HPMC K4M, 10.67%, w/w Na alginate, 1.33%, w/w Carbomer 934P, and 9.33%, w/w NaHCO₃ delivered the greatest formulations to create 24-hour supported release tablets with ideal floating

conduct and palatable physicochemical attributes. Moreover, the *in-vitro* release study uncovered that the planned SR tablet had essentially lower C_{max} and higher T_{max} contrasted with the ordinary tablet. Therefore, defined SR tablets safeguarded persevering convergence of plasma as long as 24 h. Taking everything into account, to recommend a superior drug delivery framework with a steady,

extended-release, bringing about improved retention and fewer reactions, planned CP-HPMC-SA based imatinib mesylate floating supported release tablets can be a promising contender for malignant growth chemotherapy. Release kinetics correlation coefficient (R2) parameter of Imatinib mesylate from the prepared floating sustained-release tablets shown in **Table 14**.

TABLE 14: RELEASE KINETICS CORRELATION COEFFICIENT (R2) PARAMETER OF IMATINIB MESYLATE FROM THE PREPARED FLOATING SUSTAINED-RELEASE TABLETS²⁷

Formula code	R2	Diffusional exponent (n)	Order of release	Zero Order	First Order	Higuchi	Hixson-Crowell	Weibull
F1	0.9802	0.3610	Fickian	0.9378	0.9591	0.9881	0.8939	0.8846
F2	0.9797	0.3762	Fickian	0.9336	0.9629	0.9850	0.8891	0.8872
F3	0.9895	0.3904	Fickian	0.9314	0.9773	0.9893	0.8766	0.8865
F4	0.9902	0.4001	Fiction	0.9123	0.9743	0.9818	0.8540	0.8779
F5	0.9933	0.5018	Non-Fickian	0.9668	0.8517	0.9942	0.9120	0.9878
F6	0.9936	0.5223	Non-Fickian	0.9733	0.8333	0.9948	0.9162	0.9860
F7	0.9769	0.4793	Non-Fickian	0.9887	0.9867	0.9882	0.9508	0.9709
F8	0.9778	0.4514	Non-Fickian	0.9855	0.9970	0.9911	0.9469	0.9584

J. Fus (2018)²⁸ examine gastric floating tablets that have the elements of long-haul gastric maintenance supported release and improving bioavailability however, the floating time and continued release is generally not fulfilled. Authors planned a novel gastric floating framework by joining compacted tablets with 3D printed gadgets, wherein a riboflavin tablet was contained into a gadget, named tablet-in-gadget (TiD) frameworks. Marketed poly fibers were utilized for 3D printing of the body and top of the gadget. Four sorts of TiD frameworks were readied, including non-net, halfway symmetric two-fold net, single-net, and unusual twofold net. They were structured and indicated great floating capacity, albeit just the last

two TiD frameworks were chosen because of the ideal drug release. Compacted riboflavin tablets were set up with fast drug release; however, the release was profoundly impeded by the gadgets because of the obstruction impact and the slurry development. The single-net and twofold net TiD frameworks accomplished the combined release of 41% and 62% at 72 h, separately. The long haul (>72 h) gastric floating capacity of TiD frameworks was additionally exhibited on the hare models by the CT examination. TiD frameworks are suitable for oral organization dependent on their fulfilled floating capacity and controlled release, the release of riboflavin from the compressed tablets shown in **Fig. 3**




FIG. 3: RELEASE OF RIBOFLAVIN FROM THE COMPRESSED TABLETS²⁸

Huanbutta *et al.*, (2000)²⁹ examine to create a floating drug delivery framework by sublimation of ammonium carbonate. The core tablets contain a

model drug, hydrochlorothiazide, and different levels of AMC. The tablets were then covered with various measures of the polyacrylate polymers.

The coated tablets were kept at encompassing temperature (25 °C) or relieved at 70 °C for 12 h before further examination. The floating and drug release practices of the tablets were acted in simulated gastric liquid USP without pepsin at 37 °C. The outcomes indicated that a high measure of AMC prompted the floating of the tablets. The coated tablets containing 40 and a half AMC drifted longer than 8 h with an opportunity to-buoyancy of around 3 min. The sublimation of AMC from the center tablets diminished the thickness of the framework, causing the floating of the tablets. The tablets covered with Eudragit® RL100 floating at a quicker rate than those of Eudragit. Indeed, even the covering level of polymer didn't impact an opportunity to-buoy and floating time of covered tablets containing a similar measure of AMC; the drug release from the tablets covered with higher covering levels of polymer demonstrated more slow drug release. The outcomes proposed that the sublimation method utilizing AMC is promising for the improvement of the floating drug delivery framework. Drug release profiles of floating tablets are shown in **Fig. 3**.




FIG. 4: DRUG RELEASE PROFILES OF FLOATING TABLETS²⁶

CONCLUSION: Drug ingestion in the gastrointestinal tract is a profoundly variable technique, and dragging out gastric maintenance of the measurement structure expands the ideal opportunity for sedate retention. FDDS vows to be a potential methodology for gastric maintenance. Even though there are several challenges to be worked out to accomplish delayed gastric maintenance, countless organizations are centering toward commercializing this strategy.

ACKNOWLEDGEMENT: Authors are profusely thankful to the Principal, Department of

Pharmaceutics, MAEER's Maharashtra Institute of Pharmacy, Kothrud, Pune for their valuable suggestions and guidance.

CONFLICTS OF INTEREST: We declare that no conflicts of interest

REFERENCES:

1. Patel G and Siddaiah M: Formulation and evaluation of effervescent tablets, a review. *Journal of Drug Delivery and Therapeutics* 2018; 8(6): 296-03.
2. Dallas RT, Sharma S and Sharma M: Formulation and evaluation of gastroretentive floating tablets of lafutidine, *Journal of Drug Delivery and Thera* 2018; 8(5): 393-399
3. Soni H, Ghulaxe C, Upadhyay S and Pillai S: Development and *in-vitro* evaluation of an oral floating tablet of metronidazole. *Journal of Drug Delivery and Therapeutics* 2018; 8(2): 83-86.
4. Agrawal P and Banjare AT: Formulation and evaluation of directly compressed floating tablets of candesartan cilexetil for gastro retentive drug delivery. *Research Journal of Pharmacy and Tech* 2018; 11(7): 2804-08.
5. Sharma A, Gupta AK, Gupta MK and Sharma VA: Review: formulation and characterization of fast dissolving tablet of carvedilol. *Journal of Drug Delivery and Therapeutics* 2019; 9(3): 749-52.
6. Tezyk M, Milanowski B, Ernst A and Lulek J: Recent progress in continuous and semi-continuous processing of solid oral dosage forms: a review. *Drug Development, and Industrial Pharmacy* 2016; 42(8): 1195-14.
7. Aleksovski A, Dreu R, Gašperlin M and Planinšek O: Mini-tablets: a contemporary system for oral drug delivery in targeted patient groups. *Expert Opinion on Drug Delivery* 2015; 12(1): 65-84.
8. Gullapalli RP and Mazzitelli CL: Gelatin and non-gelatin capsule dosage forms. *Journal of Pharmaceutical Sciences* 2017; 106(6): 1453-65.
9. Park BJ, Choi HJ, Moon SJ, Kim SJ, Bajracharya R, Min JY and Han HK: Pharmaceutical applications of 3D printing technology: current understanding and future perspectives. *Journal of Pharmaceutical Investigation* 2019; 49: 575-85.
10. Gioumouxouzis CI, Baklavariadis A, Katsamenis OL, Markopoulou CK, Bouropoulos N, Tzetzis D and Fatouros DA: 3D printed bilayer oral solid dosage form combining metformin for prolonged and glimepiride for immediate drug delivery. *European Journal of Pharmaceutics and Biopharmaceutics* 2018; 120: 40-52.
11. Niharika MG, Krishnamoorthy K and Akkala M: Overview on floating drug delivery system. *International Journal of Applied Pharmaceutics* 2018; 10(6): 65-71.
12. Vo A, Feng QX, Morott JT, Pimparade MB, Tiwari RV, Zhang F and Repka M: A novel floating controlled release drug delivery system prepared by hot-melt extrusion. *Euro Journal of Pharma and Biopharma* 2016; 98: 108-21.
13. Begum RU: Formulation development and *in-vitro* evaluation of sitagliptin floating tablets. *Development and Delivery* 2019; 2(1): 25-30.
14. Aditya S, Vishkha C, Tahir N, Neelesh M, Namrata R and Vyas I: Formulation and evaluation of floating tablet of tropisetron Sharma. *Journal of Drug Delivery and Therapeutics* 2019; 9(2): 44-46.
15. Chakraborty TN and Saini VR: Formulation and evaluation of controlled release floating tablets of cefixime

- using hydrophilic polymers. International Research Journal of Pharmacy 2019; 10(1):171-75.
16. Collins O and Uwumagbe MU: Formulation and evaluation of effervescent floating matrix tablets of a biguanide using grewia mollis gum. Asian journal applied sciences 2019; 12 (2): 91-98.
 17. Eswaraiiah C: Design and *in-vitro* characterization of floating tablets of metronidazole. Asian Journal of Pharmaceutical and Clinical Research 2019; 12(3): 539-44.
 18. Wang S, Wen H; Li P, Cui M, Sun W, Wang H, Liu H, Li S, Pan W and Yang X: Formulation and evaluation of gastric-floating controlled-release tablets of ginkgolides. Journal of Drug Delivery Science and Technology 2019; 51 (1): 7-17.
 19. Swain RP, Pendela S and Panda S: Formulation and evaluation of gastro-bilayer floating tablets of simvastatin as immediate release layer and atenolol as sustained release layer. Indian Journal of Pharmaceutical Sciences 2016; 78(4): 458-68.
 20. Raza A, Bukhari NI, Karim S, Hafiz MA and Hayat U: Floating tablets of minocycline hydrochloride: formulation, *in-vitro* evaluation and optimization. Future Journal of Pharmaceutical Sciences 2017; 10(3): 161.
 21. Senjoti FG, Mahmood S, Jaffri JM and Mandal UK: Design and *in-vitro* evaluation of sustained release floating tablets of metformin HCl based on effervescence and swelling. Iranian Journal of Pharmaceutical Research 2016; 15(1): 53-70.
 22. Rawat S, Sangali S and Gupta A: Formulation and evaluation of floating matrix tablets of acyclovir using 3² factorial design. Research Journal of Pharmaceutical Dosage Forms and Technology 2018; 10(1): 01-09.
 23. Li Q, Guan X, Cui M, Zhu Z, Chen K, Wen H, Jia D, Hou J, Xu W and Yang X: Preparation and investigation of novel gastro-floating tablets with 3D extrusion-based printing. International Journal of Pharmaceutics 2018; 15: 325-32.
 24. Chai X, Chai H, Wang X, Yang J, Li J, Zhao Y, Cai W, Tao T and Xiang X: Fused deposition modeling (FDM) 3D printed tablets for intragastric floating delivery of domperidone. Scientific Reports 2017; 7(1): 2829.
 25. Diós P, Nagy S, Pál S, Pernecker T, Kocsis B, Budán F, Horváth I, Szigeti K, Bölskei K and Máthé D: Preformulation studies and optimization of sodium alginate based floating drug delivery system for eradication of helicobacter pylori. European Journal of Pharmaceutics and Biopharmaceutics 2015; 96: 196-06.
 26. Huanbutta K and Sangnim T: Design and development of zero-order drug release gastroretentive floating tablets fabricated by 3d printing technology. Journal of Drug Delivery Science and Technology 2019; 12: 77.
 27. Kadivar A, Kamalidehghan B, Javar HA, Davoudi ET, Zaharuddin ND, Sabeti B, Chung LY and Noordin MI: Formulation and *in-vitro*, *in-vivo* Evaluation of Effervescent Floating Sustained-Release Imatinib Mesylate Tablet. PLOS One 2015; 2; 10(6): 1-23.
 28. Fu J, Yin H, Yu X, Xie C, Jiang H, Jin Y and Sheng F: Combination of 3D Printing Technologies and Compressed Tablets for Preparation of Riboflavin Floating Tablet-in-Device (TiD) Systems. International Journal of Pharmaceutics 2018; 549(1-2): 370-79.
 29. Huanbutta K, Limmatvapirat S, Sungthongjeen S and Sriamornsak P: Novel Strategy to Fabricate Floating Drug Delivery System Based on Sublimation Technique. The American Associ of Pharma Scientists 2016; 17(3): 693-9

How to cite this article:

Pawar R and Jagdale S: The study on optimization of solid oral floating tablets-a review. Int J Pharm Sci & Res 2021; 12(3): 1399-11. doi: 10.13040/IJPSR.0975-8232.12(3).1399-11.

All © 2013 are reserved by International Journal of Pharmaceutical Sciences and Research. This Journal licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License.

This article can be downloaded to **Android OS** based mobile. Scan QR Code using Code/Bar Scanner from your mobile. (Scanners are available on Google Playstore)